Apricus Biosciences, Inc., a biopharmaceutical company, focuses on the development of product candidates in the areas of urology and rheumatology. The company develops Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction; and RayVa, which is in Phase IIa clinical trial to treat Raynaud's phenomenon associated with scleroderma. It has a license and stock issuance agreement with Forendo Pharma Ltd. to develop and commercialize fispemifene, a tissue-specific selective estrogen receptor modulator to treat symptomatic secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms in men. Apricus Biosciences, Inc. operates in Europe, Canada, Latin America, and the Asia Pacific. The company was formerly known as NexMed, Inc. and changed its name to Apricus Biosciences, Inc. in September 2010. Apricus Biosciences, Inc. was founded in 1987 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:APRI
CUSIPN/A
Phone858-222-8041
Debt
Debt-to-Equity RatioN/A
Current Ratio3.75
Quick Ratio3.75
Price-To-Earnings
Trailing P/E Ratio-0.29
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.76 million
Price / Sales1.18
Cash FlowN/A
Price / CashN/A
Book Value$0.29 per share
Price / Book1.00
Profitability
EPS (Most Recent Fiscal Year)($0.99)
Net Income$320,000.00
Net MarginsN/A
Return on Equity-216.07%
Return on Assets-152.06%
Miscellaneous
Employees11
Outstanding Shares23,440,000
Market Cap$6.68 million
Apricus Biosciences (NASDAQ:APRI) Frequently Asked Questions
What is Apricus Biosciences' stock symbol?
Apricus Biosciences trades on the NASDAQ under the ticker symbol "APRI."
How were Apricus Biosciences' earnings last quarter?
Apricus Biosciences Inc (NASDAQ:APRI) released its earnings results on Thursday, August, 9th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.14) by $0.04. View Apricus Biosciences' Earnings History.
When is Apricus Biosciences' next earnings date?
What price target have analysts set for APRI?
1 Wall Street analysts have issued 12-month price targets for Apricus Biosciences' stock. Their forecasts range from $1.00 to $1.00. On average, they anticipate Apricus Biosciences' stock price to reach $1.00 in the next twelve months. This suggests a possible upside of 244.8% from the stock's current price. View Analyst Price Targets for Apricus Biosciences.
What is the consensus analysts' recommendation for Apricus Biosciences?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apricus Biosciences in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Apricus Biosciences.
Who are some of Apricus Biosciences' key competitors?
Some companies that are related to Apricus Biosciences include Nemus Bioscience (NMUS), Innovus Pharmaceuticals (INNV), Nuvo Pharmaceuticals (NRIFF), Sernova (SEOVF), Q BioMed (QBIO), Adial Pharmaceuticals (ADIL), Gemphire Therapeutics (GEMP), X T L Biopharmaceuticals (XTLB), Eyegate Pharmaceuticals (EYEG), RegeneRx Biopharmaceuticals (RGRX), Soligenix, Inc. Common Stock (SNGX), Akari Therapeutics (AKTX), ERBA Diagnostics (ERBA), Diffusion Pharmaceuticals (DFFN) and Pernix Therapeutics (PTX).
Who are Apricus Biosciences' key executives?
Apricus Biosciences' management team includes the folowing people:
- Mr. Richard W. Pascoe, CEO, CFO, Sec., Principal Accounting Officer & Director (Age 54)
- Mr. Brian T. Dorsey, Sr. VP & Chief Devel. Officer (Age 49)
- Mr. Neil C. Morton, Sr. VP & Chief Bus. Officer (Age 42)
- Ms. Kelly Deck, Exec. Director of Fin.
- Ms. Mary Naggs, VP & Gen. Counsel
Has Apricus Biosciences been receiving favorable news coverage?
News coverage about APRI stock has trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Apricus Biosciences earned a coverage optimism score of 0.16 on Accern's scale. They also gave media stories about the company an impact score of 45.51 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term. View Recent Headlines for Apricus Biosciences.
How do I buy shares of Apricus Biosciences?
Shares of APRI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Apricus Biosciences' stock price today?
One share of APRI stock can currently be purchased for approximately $0.29.
How big of a company is Apricus Biosciences?
Apricus Biosciences has a market capitalization of $6.68 million and generates $5.76 million in revenue each year. The company earns $320,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. Apricus Biosciences employs 11 workers across the globe.
How can I contact Apricus Biosciences?
Apricus Biosciences' mailing address is 11975 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The company can be reached via phone at 858-222-8041 or via email at [email protected]
MarketBeat Community Rating for Apricus Biosciences (NASDAQ APRI)
MarketBeat's community ratings are surveys of what our community members think about Apricus Biosciences and other stocks. Vote "Outperform" if you believe APRI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APRI will underperform the S&P 500 over the long term. You may vote once every thirty days.
